Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Integra LifeSciences Holdings Corporation (IART) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Integra’s Form 8-K filings and related exhibits offer insight into its financial reporting practices, governance programs, and key operational updates as a global medical technology company focused on neurosurgery and tissue reconstruction.
Recent Form 8-K filings include results of operations and financial condition for specific quarters, where Integra furnishes press releases detailing revenues, segment performance for Codman Specialty Surgical and Tissue Technologies, and reconciliations between GAAP and non-GAAP measures. These filings explain how management uses metrics such as organic revenues, adjusted EBITDA, adjusted net income, adjusted gross margin, adjusted earnings per diluted share, net debt, free cash flow, and adjusted free cash flow conversion to evaluate performance and compare results over time.
Other 8-K filings address governance and executive programs, such as a change in control severance program for certain executives. That program, as described in the filing, outlines severance payments, bonus treatment, COBRA premium subsidies, outplacement services, and potential adjustments for excise tax exposure in connection with qualifying terminations following a change in control, with a defined term and renewal provisions overseen by the Board’s Compensation Committee.
Through this filings page, users can review how Integra discusses topics such as quality and compliance initiatives, manufacturing transitions, and the financial impact of structural optimization, acquisition and divestiture-related charges, EU Medical Device Regulation costs, recall-related charges, and impairment charges. Stock Titan enhances access to these documents with AI-powered summaries that help explain technical sections of 10-Ks, 10-Qs, and 8-Ks, highlight key adjustments and definitions, and surface important trends without replacing the underlying filings.
Filings are updated in near real time from the SEC’s EDGAR system, and users can also monitor items related to executive compensation structures and other governance matters. For investors analyzing IART, this page serves as a focused entry point into Integra’s official regulatory record, with tools to interpret complex disclosures more efficiently.